Get the Stockscreener App
1.82
0.55%
-0.01
After Hours:
1.70
-0.12
-6.59%
Proqr Therapeutics N V stock is traded at $1.82, with a volume of 70,929.
It is down -0.55% in the last 24 hours and down -9.90% over the past month.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
See More
Previous Close:
$1.83
Open:
$1.83
24h Volume:
70,929
Relative Volume:
0.63
Market Cap:
$151.93M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-2.4819
EPS:
-0.7333
Net Cash Flow:
$21.84M
1W Performance:
+8.33%
1M Performance:
-9.90%
6M Performance:
-20.52%
1Y Performance:
+40.00%
1-Day Range:
$1.81
$1.94
1-Week Range:
$1.65
$2.05
52-Week Range:
$1.11
$3.29
Proqr Therapeutics N V Stock (PRQR) Company Profile
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com UK
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $1.95 - MarketBeat
ProQR Therapeutics N.V (PRQR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Market Momentum: ProQR Therapeutics N.V (PRQR) Registers a 7.14 Increase, Closing at 1.80 - The Dwinnex
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving Average of $1.96 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $1.96 - Defense World
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - GlobeNewswire
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - StockTitan
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Above 50-Day Moving Average of $1.90 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90 - Defense World
A look into ProQR Therapeutics N.V (PRQR)’s deeper side - SETE News
What technical indicators reveal about PRQR stock - US Post News
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - Yahoo Finance UK
ProQR Therapeutics NV (FRA:0PQ) Financial Strength : 3 (As of Jun. 2024) - GuruFocus.com
Reviewing ProQR Therapeutics (NASDAQ:PRQR) and OptiNose (NASDAQ:OPTN) - Defense World
ProQR Therapeutics NV (FRA:0PQ) Enterprise Value : €86.81 Mil (As of Aug. 17, 2024) - GuruFocus.com
Comparing Moleculin Biotech (NASDAQ:MBRX) & ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR: Q2 Earnings Snapshot - San Antonio Express-News
ProQR: Q2 Earnings Snapshot - San Francisco Chronicle
ProQR Therapeutics N.V. Financial Performance Review - TipRanks
ProQR Announces Second Quarter 2024 Operating and Financial Results - GlobeNewswire
ProQR Announces Second Quarter 2024 Operating and Financial Results - Yahoo Finance
Virtu Financial LLC Has $59,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Acadian Asset Management LLC Takes $56,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $2.00 - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Below Two Hundred Day Moving Average of $2.00 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $2.01 - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $2.01 - MarketBeat
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected - Simply Wall St
StockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to Hold - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Sees Significant Drop in Short Interest - MarketBeat
StockNews.com Upgrades ProQR Therapeutics (NASDAQ:PRQR) to “Hold” - Defense World
Individual investors account for 45% of ProQR Therapeutics N.V.'s (NASDAQ:PRQR) ownership, while institutions ... - Yahoo New Zealand News
ProQR (PRQR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Movies UK
RFG Advisory LLC Makes New $73,000 Investment in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly - Yahoo Canada Shine On
ProQR Announces Upcoming Investor Conferences in November and December - Quantisnow
Lilly and ProQR to Expand RNA Editing Collaboration - Quantisnow
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock? - Zacks Investment Research
Institutions own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) shares but retail investors control 46% of the ... - Yahoo Finance UK
Institutions own 25% of ProQR Therapeutics N.V. (NASDAQ:PRQR) shares but retail investors control 46% of the company - Yahoo Finance
ProQR Therapeutics (NASDAQ:PRQR) Lowered to Sell at StockNews.com - Defense World
StockNews.com Lowers ProQR Therapeutics (NASDAQ:PRQR) to Sell - MarketBeat
ProQR (PRQR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo New Zealand News
A stock that deserves closer examination: ProQR Therapeutics N.V (PRQR) – US Post News - US Post News
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - Markets Insider
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - EIN News
PRQRProQR Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Xilio Therapeutics Appoints Aoife Brennan and James Shannon to its Board of Directors - citybiz
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors - ForexTV.com
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):